2026-525480-41-00
EU Clinical Trials Information System
- Trial ID
- T-ctis-2026-525480-41-00
- Registry
- EU Clinical Trials Information System
- NCT number
- NCT07759245
- CTIS number
- 2026-525480-41-00
- Sponsor, as registered
- Eli Lilly & Co.
- Phase
- Therapeutic exploratory (Phase II)
- Indication
- Pulmonary Disease, Chronic Obstructive
- Status
- Authorised
- Start date
- 17/09/2026
- Primary completion
- CTIS does not publish one.
- Member states concerned
- Austria, Czechia, Germany, Denmark, France, Hungary, Poland, Romania
- Sites
- 48
Member states whose regulator has a decision on this trial.
euclinicaltrials.euctis registryverified 2026-11-07
Notes on the record
Supersedes the row verified 2026-10-26 (kept), per DATA LAYER rule 4. Read from the CTIS public API retrieve endpoint 2026-11-07 (https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-525480-41-00; response sha256 498935ffac43). primary_completion_date is EMPTY because CTIS does not publish one. Per-state authorisation is NOT recorded and status codes are recorded verbatim, not decoded: the registry publishes no key. Brenipatide, Phase 2 (J2S-MC-GZMV). France mscPublicStatusCode 3 to 4 (collector, 6 Nov); on this read France 4, Romania 4, Czechia 4, Poland 4, Hungary 4, Germany 4, Denmark 2, Austria 2; member states unchanged (AT, CZ, DE, DK, FR, HU, PL, RO).
Company
Through brenipatide (LY3537031): Lilly
Cited in
Issues quoting 2026-525480-41-00 in their own text.